Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke
Retrieved on:
Thursday, November 4, 2021
Biotechnology, FDA, Pharmaceutical, Health, Newton, Safety, Texas Medical Center, A&B, Achievement, Memorial Hermann–Texas Medical Center, Industry, Clinical trial, Chapter Three, Euronext Growth, Severe acute respiratory syndrome coronavirus 2, Disease, GPVI, Growth, COVID-19, Stroke, Standard of care, Forward-looking statement, National Institute, Thrombectomy, Children's Memorial Hermann Hospital, ISIN, Biotechnology, Environment, IPO, Medicine, Rankine scale, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRS, Silchester International Investors, Patient, Bleeding, FDA, VI, IND, Pharmaceutical industry, glenzocimab (ACT017), the Therapeutic Candidate, glenzocimab and COVID-19, ACTICOR BIOTECH, GLENZOCIMAB (ACT017), THE THERAPEUTIC CANDIDATE, GLENZOCIMAB AND COVID-19, ACTICOR BIOTECH
This active IND represents a significant milestone and marks the launch in the US of the Phase 2/3 clinical trial with glenzocimab in acute ischemic stroke as an add-on therapy to standard of care for this indication.
Key Points:
- This active IND represents a significant milestone and marks the launch in the US of the Phase 2/3 clinical trial with glenzocimab in acute ischemic stroke as an add-on therapy to standard of care for this indication.
- The development of new therapeutic options for the treatment of the acute phase of ischemic stroke without increasing the bleeding risk, is a major medical need of the coming years.
- The FDA acceptance of an IND application for glenzocimab and the clinical program that will be conducted by Acticor Biotech in the US constitute important steps to offer new safe treatments to stroke patients, says Pr.
- Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab).